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Abstracts / Urological Science 26 (2015) S50eS81 S59prostate or bladder cancer within 3 months peri-operatively were
excluded. ICD-9 codes for hypertension (HTN), diabetes mellitus (DM),
cerebral vascular disease (CVA), spinal stenosis (SS), and herniated inter-
vertebral disc (HIVD) were used for disease conﬁrmation only when the
diagnoses existed at least one year before TURP. Descriptive and compar-
ative analyses were performed.
Results: There were 2597 TURPs analyzed, including 2497 TURPs only
(group A) and 100 TURPs with combined with TUIBN (group B). The hos-
pitalization days mainly ranged from 3 to 5 days. The mean age was 72.45,
with 72.69 and 71.86 in group A and B respectively. Among all patients
included, 245 of them were associated with AUR (9.43%), with 9.69% and
3.00% in group A and B (P¼ 0.022). Patient who had previous AUR episodes
within 2 months before TURP was of 23.64%, but pre-OP AUR was not
signiﬁcantly associatedwith higher post-OPAUR rate (11.24%) than no AUR
before TURP (8.88%) (P ¼ 0.083). About co-morbidities, HTN, DM, CVA, SS,
and HIVD were not signiﬁcant risk factors for AUR after TURP (P ¼ 0.934,
0.426, 0.111, 0.976, and 0.362 respectively). In multivariate analysis, com-
bined TUIBN and younger age are the only two signiﬁcant factors associ-
ated with less AUR rates after smaller weight TURPs. (P ¼ 0.041 and 0.028
respectively)
Conclusion: In Taiwan, most patients treated with smaller weight TURP
without combined TUIBN. However, AUR rate is signiﬁcantly lower in pa-
tients receiving combined TURP with TUIBN, regardless of pre-OP Foley
indwelling or other co-morbidities. Although further randomized clinical
trials are still necessary, it implies that for patients with bladder outlet
obstruction treated with smaller resection weight of TURP, combined
TUIBN may be beneﬁcial, especially regarding the post-OP AUR episodes.
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Purpose: Pseudoephedrine is a widely used sympathomimetic amine on
patients with rhinorrhea and allergic rhinitis. The vasoconstriction effect is
believed to be principally an on a-adrenergic receptor response. Urinary
retention was considered contraindication while use on patients with
concomitant prostatic hypertrophy needs precautions. Although not one of
the most seen overall side effects, patients suffered from urinary retention
or dysuria after taking pseudoephedrine may come to urologists for help.
The study aimed to elucidate the impact of pseudephedrine on lower
urinary tract symptoms (LUTS) in patients without self-reported voiding
dysfunction.
Materials and Methods: All male patients came to our Otolaryngology
OPD for acute or chronic rhinitis was asked by doctors to make sure they
are free from voiding dysfunction by self-reported. Then patients with
voiding problems or under current medication treatment for LUTS were
excluded. Other patients were given medication according to the indi-
vidual clinical symptoms. Once pseudoephedrine was prescribed, Inter-
national Prostate Symptom Score (IPSS) questionnaires were ﬁlled in by
the patients. After treatment with pseudoephedrine for 1 week, a post-
medication IPSS questionnaire was ﬁlled for follow-up. Total 68 patients
complete the survey. Age, IPSS total score, IPSS voiding score, IPSS voiding
score, quality of life score were analyzed for correlation.
Results: The average age of total 68 patients was 38.7 year-old (15-71
year-old). The average IPSS total score before and after medication was
4.81 and 6.54 respectively. The average IPSS voiding / storage score
before medication were 2.53/2.35 and changed to 3.68/2.87 after medi-
cation. Quality of life score based on voiding condition were 1.88 and
2.03 before and after medication. Independent T-test was used to eval-
uate the predictors for worsen (deﬁned as increased IPSS-T) and stable
(deﬁned as equal or decreased IPSS-T) voiding condition. Age, pre-
medication IPSS-T and IPSS-V were signiﬁcant predictors for worsen
voiding function after taking pseudoephedrine. Quality of life score based
on voiding condition before and after medication showed no signiﬁcantly
difference.Conclusion: Patients who were self-reported free from voiding dysfunc-
tion may still suffer from increased LUTS after pseudoephedrine. Age and
pre-medication IPSS-V score could be predictors for the presence of
increased LUTS.
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Surgery, Cathay General Hospital, Taiwan
Purpose: To review clinical outcomes of bladder augmentation with
ileocystoplasty for ketamine-associated ulcerative cystitis secondary to
long-term ketamine abuse.
Materials and Methods: We performed bladder augmentation with ileo-
cystoplasty for 8 patients with refractory symptoms of ketamine cystitis
(severe bladder pain, micturition pain, urgency, frequency, and/or urinary
tract damage such as hydronephrosis, and contracted bladder). Every pa-
tient had been treated conservatively with medication at OPD or referred
from other hospital. Intravenous pyelography and/or cystoscopy were
obtained before they had received surgical intervention. Their history of
ketamine consumption, symptoms, history of treatment, surgical infor-
mation and post-operative condition was obtained from medical records
and then summarized.
Results: Between 2007 and 2015, eight patients (seven males and one
female), aged 26-48 years (mean 32.7 years) underwent this procedure as
indicated. The duration of ketamine abuse ranged from 2-15 years (mean
6.8 years). Contracted bladder was noted in all patients, hydronephrosis in
2 and hydroureter in 1 under intravenous pyelography examination. Post-
operative hospitalization ranged from 12-47 days (mean 22.4 days). One
patient had ileus post colono-enteric bypass post-operative within 90
days. One had impaired renal function before surgery and received inter-
mittent hemodialysis 5 years after surgery. Most of patients followed up at
OPD within 1 year and loss follow-up after. All patients reported marked
improvement in micturition pain and urinary frequency, which greatly
enhance their quality of life.
Conclusion: This study demonstrated that bladder augmentation is
effective in relieving refractory symptoms of ketamine-associated ul-
cerative cystitis. Cessation of ketamine is the most important way to
prevent recurrence of above symptoms. This is not only a medical issue,
but timely intervention of social workers and psychological support are
also essential.
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Purpose: To investigate the long-term therapeutic effects, patient adher-
ence of combination therapyof 5-a-reductase inhibitor (5ARI) and alpha-
blocker, and the predictors for withdrawal of medication in patients with
clinical benign prostatic hyperplasia (BPH).
Materials and Methods: BPH patients with lower urinary tract symptoms
(LUTS) under combination therapy were retrospectively analyzed from 1
to 12 years span. The therapeutics effects were assessed by International
Prostatic Symptoms Score (IPSS) and quality of life index (QoL-I), total
prostatic volume (TPV), maximum ﬂow rate (Qmax), voided volume
(VoL), prostatic speciﬁc antigen (PSA) at baseline and annually. The
reason and predictors of discontinued combination therapy were also
investigated.
Results: A total of 625 patients aged 38 to 97 (mean 73) years where
enrolled retrospectively with at least 1 year and the longest period of 12
years follow-up. The mean year follow up was 3 years. All measured pa-
rameters showed signiﬁcant improvement after combination therapy. The
